Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy.
Dermatol Ther. 2021 Mar;34(2):e14832. doi: 10.1111/dth.14832. Epub 2021 Feb 11.
Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol). Several studies have been published about oral oxybutynin, but no studies focused on the achievement of complete clinical and Qol response. The aim of this study was to report our real-life experience with oral oxybutynin in patients with severe hyperhidrosis significantly affecting their Qol. In this cohort retrospective study, we enrolled, in a 3-year period, patients affected by severe hyperhidrosis with poor Qol, continuously treated with oral oxybutynin. Our outcome was the obtainment of complete clinical and Qol improvement. A systematic review of the literature was also performed reporting efficacy and safety of oral oxybutynin for primary hyperhidrosis. We enrolled 62 patients, of which 53 (85.5%) received a mean daily dose of 10 mg and nine (15.5%) of 5 mg. Complete clinical response was achieved in 77.4% (48/62) of cases, while complete Qol improvement occurred in 51.6% (32/62) of cases. Adverse events were only reported as mild, with dry mouth being the most frequently observed (16.1%). Kaplan-Meier survival analysis highlighted that both median clinical and Qol complete responses were reached after 1 year of continuous therapy with oral oxybutynin. The main limitation of our study is the small number of patients enrolled. Long-term therapy with oral oxybutynin for severe hyperhidrosis, continuously administered at a mean daily dosage of 5 to 10 mg, allowed the majority of our patients to reach both clinical and Qol complete improvement, without significant adverse events.
多汗症是一种过度出汗的疾病，严重影响患者的生活质量 (Qol)。已经发表了几项关于口服奥昔布宁的研究，但没有研究关注完全临床和 Qol 反应的实现。本研究旨在报告我们在严重影响生活质量的多汗症患者中使用口服奥昔布宁的真实临床经验。在这项回顾性队列研究中，我们在 3 年内招募了因严重多汗症而生活质量较差且持续接受口服奥昔布宁治疗的患者。我们的研究结果是获得完全的临床和生活质量改善。我们还对文献进行了系统评价，报告了口服奥昔布宁治疗原发性多汗症的疗效和安全性。我们共招募了 62 名患者，其中 53 名（85.5%）接受了 10mg 的平均日剂量，9 名（15.5%）接受了 5mg 的平均日剂量。77.4%（48/62）的病例达到了完全的临床反应，而 51.6%（32/62）的病例达到了完全的生活质量改善。只有轻度不良反应报告，最常见的是口干（16.1%）。Kaplan-Meier 生存分析突出表明，口服奥昔布宁连续治疗 1 年后，中位数临床和 Qol 完全反应均达到。本研究的主要局限性是纳入的患者数量较少。长期（1 年）口服奥昔布宁治疗严重多汗症，以 5 至 10mg 的平均日剂量持续给药，使我们的大多数患者达到了完全的临床和 Qol 改善，没有明显的不良反应。
